Q4 2021 Adjusted Revenues was $1.5 million 1, an increase of 312% over Q4 2020 2021 Pro Forma TTM Adjusted Revenues was $7.0 million 1, an increase of 126% over 2020 Current Pro Forma 2021 Adjusted ...
Comprehensive etavopivat Phase I SCD trial completed with results supporting tolerability and benefits in hematologic biomarkers and red blood cell health; pivotal Phase II/III trial enrolling Initial ...
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today provided a ...
Combined Pro Forma 2021 Revenue of $547 to $570 Million and Combined Pro Forma Adjusted EBITDA of $131 to $136 Million Before Synergies ALPHARETTA, Ga., Sept. 17, 2021 /PRNewswire/ -- Priority ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback